<DOC>
	<DOCNO>NCT02643303</DOCNO>
	<brief_summary>This open-label , multicenter Phase 1/2 study CTLA-4 antibody , tremelimumab , PD-L1 antibody , durvalumab ( MEDI4736 ) , combination tumor microenvironment ( TME ) modulator polyICLC , TLR3 agonist , subject advance , measurable , biopsy-accessible cancer .</brief_summary>
	<brief_title>A Phase 1/2 Study In Situ Vaccination With Tremelimumab IV Durvalumab Plus PolyICLC Subjects With Advanced , Measurable , Biopsy-accessible Cancers</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Carcinoma , Merkel Cell</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Poly ICLC</mesh_term>
	<mesh_term>Poly I-C</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Carboxymethylcellulose Sodium</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<criteria>1 . Subjects must histologic confirmation advance , biopsyaccessible , measurable cancer follow histology : Nonviralassociated head neck squamous cell carcinoma ( HNSCC ) HPVassociated HNSCC failure prior therapy Locally recurrent breast cancer Sarcoma Merkel Cell Carcinoma ( MCC ) Cutaneous T cell Lymphoma ( CTCL ) Melanoma failure available therapy GU cancer accessible metastasis ( e.g. , bladder , renal ) Any solid tumor mass accessible without image 2 . Subjects measurable disease . 3 . Any number prior systemic therapy . 4 . Performance status 01 . 5 . Laboratory parameter : Absolute neutrophil count ( ANC ) ≥ 1000/mm3 ; Platelets ≥ 100,000/mm3 ; Hemoglobin ( Hgb ) ≥ 9 g/dL ; HgbA1C ≤ 7.5 % ; Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 × upper limit normal ( ULN ) ; Bilirubin ≤ 2.5 × ULN ( ≤ 4 × ULN subject Gilbert 's disease ) ; Alkaline phosphatase ≤ 2.5 × ULN ; Creatinine ≤ 1.5 × ULN . 6 . Age ≥ 18 year . 7 . Able willing give valid write informed consent . 1 . Prior treatment combination CTLA4 PD1/PDL1 blockade . 2 . Participants may treat intratumorally polyICLC . 3 . Unresolved irAEs follow prior biological therapy , except stable manage irAEs may acceptable ( e.g. , hypothyroidism hypopituitarism appropriate replacement ) . 4 . Subjects history evidence upon physical examination central nervous system ( CNS ) disease , include primary brain tumor , seizures control standard medical therapy , brain metastasis , , within 6 month first date treatment study , history cerebrovascular accident ( CVA , stroke ) , transient ischemic attack ( TIA ) subarachnoid hemorrhage . 5 . Subjects clinically significant cardiovascular disease , include : 1 . Uncontrolled hypertension , define systolic blood pressure ( BP ) &gt; 150 mmHg diastolic BP &gt; 90 mmHg . 2 . Myocardial infarction unstable angina within 6 month first date treatment study . 3 . History serious ventricular arrhythmia ( i.e. , ventricular tachycardia ventricular fibrillation ) cardiac arrhythmia require antiarrhythmic medication , except atrial fibrillation well control anti arrhythmic medication . 4 . Baseline ejection fraction ≤ 50 % assessed echocardiogram multigated acquisition ( MUGA ) scan . 5 . New York Heart Association ( NYHA ) Class II higher congestive heart failure . 6 . Grade 2 high peripheral ischemia [ brief ( &lt; 24 hour ) episode ischemia manage nonsurgically without permanent deficit ] . 6 . History pneumonitis interstitial lung disease . 7 . Active , suspect prior document autoimmune disease ( include inflammatory bowel disease , celiac disease , irritable bowel syndrome , Wegner 's granulomatosis Hashimoto 's thyroiditis ) . Participants vitiligo , type I diabetes mellitus , residual hypothyroidism due autoimmune condition require hormone replacement , psoriasis require systemic treatment , condition expect recur absence external trigger permit enroll . 8 . Other malignancy within 2 year prior entry study , except treated surgical therapy ( e.g. , localized lowgrade cervical prostate cancer ) . 9 . Subjects clinical symptom sign gastrointestinal obstruction and/or require drainage gastrostomy tube and/or parenteral hydration nutrition . 10 . Known immunodeficiency HIV , Hepatitis B , Hepatitis C positivity . Antibody Hepatitis B C without evidence active infection may allow . 11 . History severe allergic reaction unknown allergen component study drug . 12 . Other serious illness ( e.g. , serious infection require antibiotic , bleed disorder ) . 13 . Participation clinical trial involve another investigational agent within 4 week prior Day 1 study . 14 . Mental impairment may compromise ability give informed consent comply requirement study . 15 . Lack availability immunological clinical followup assessment . 16 . Women child bear potential pregnant evidence positive serum pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) nursing . 17 . Females childbearing potential use medically acceptable mean contraception . 18 . Any condition , clinical judgment treat physician , likely prevent subject comply aspect protocol may put subject unacceptable risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Durvalumab</keyword>
	<keyword>MEDI4736</keyword>
	<keyword>Tremelimumab</keyword>
	<keyword>PolyICLC</keyword>
	<keyword>Hiltonol</keyword>
	<keyword>Locally Recurrent Breast Cancer</keyword>
	<keyword>Metastatic Melanoma</keyword>
	<keyword>In Situ</keyword>
	<keyword>CTLA-4 Antibody</keyword>
	<keyword>PD-L1 Antibody</keyword>
	<keyword>TLR3 Agonist</keyword>
</DOC>